Furin inhibitor D6R suppresses epithelial-mesenchymal transition in SW1990 and PaTu8988 cells via the Hippo-YAP signaling pathway

MENG ZHOU1*, YOUJI ZHANG1*, HONG WEI1, JUNBO HE1, DAWEI WANG1, BAODING CHEN2, JIAN ZENG3, AIHUA GONG3 and MIN XU1

Departments of 1Gastroenterology and 2Ultrasound Diagnosis, Affiliated Hospital of Jiangsu University; 3Department of Cell Biology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China

Received September 25, 2016; Accepted October 3, 2017

DOI: 10.3892/ol.2017.7672

Abstract. Hexa-D-arginine (D6R), an inhibitor of furin, has potential therapeutic applications in different types of human tumor. However, the function of D6R in targeting pancreatic cancer cells remains to be elucidated. In the present study, the proliferation, invasion and migration abilities of SW1990 and PaTu8988 cells were examined using a Cell Counting Kit-8, and Transwell and wound healing assays. Subsequently, the expression of proteins associated with epithelial-mesenchymal transition (EMT) and the Hippo-yes-associated protein (YAP) pathway were detected using western blot analysis. It was revealed that D6R significantly inhibited the proliferation, migration and invasion abilities of SW1990 and PaTu8988 cells. Additionally, D6R led to the upregulation of E-cadherin (an epithelial marker), and the downregulation of N-cadherin and vimentin (mesenchymal markers) in SW1990 and PaTu8988 cells. Furthermore, the results of the present study revealed that D6R significantly affected the YAP phosphorylation level and the total YAP protein level, indicating that D6R was functionally involved in the Hippo-YAP signaling pathway. It has been suggested that D6R-suppressed EMT in SW1990 and PaTu8988 cells may occur via the Hippo-YAP pathway and that it may be a feasible drug to ameliorate the malignant phenotype of SW1990 and PaTu8988 cells.

Introduction

Furin is a member of the pro-protein convertase (PC) family that activates precursor proteins by cleaving a specific recognition sequence, and has served an important function in the activation of bacterial toxins and viral glycoproteins, in addition to the metastatic progression of certain types of tumor (1,2). It was revealed that furin may be a target for the development of potent and selective antiproteolytic agents, owing to the notable function of furin in the proteolytic activation of numerous pathogenic precursor proteins, including the pro-toxins of bacteria and viruses, such as influenza A, Ebola virus and anthrax infection (3-5). Furthermore, furin may process molecules associated with tumor aggression and metastatic potential, including transforming growth factor-β (TGF-β), membrane type 1 matrix metalloproteinase (MMP) and vascular endothelial growth factor (6-8). Furin is required for the activation of numerous pathogenic precursor proteins and therefore, furin inhibition is a logical approach to inhibiting the activation of those proteins.

In previous studies, a variety of putative inhibitors of furin have been identified, the most attractive among these being small molecule compounds, including decanoyl-RVKR-chloromethyl-ketone (CMK) (9), α1-antitrypsin Portland (α1-PDX) (10), CCG 8294 (11) and hexa-D-arginine (D6R) (12). D6R, a type of small synthetic inhibitor, is less toxic and more effective compared with other small molecule compounds in vitro, including α1-PDX, furin propeptide and proteinase inhibitor-8 (12), with inhibitory constant values for furin, PACE4 and PC1 being 0.106, 0.580 and 13.200 μM, respectively. It has been reported that D6R may be a treatment for bacterial and viral infections (4,13,14). For example, D6R appeared to block the cleavage of pseudomonas aeruginosa exotoxin A in vitro and in vivo (15), to reduce hepatitis B e-antigen secretion in patients with chronic hepatitis B viral infection and to facilitate the decrease of immune tolerance (9). However, little is known regarding the function of D6R in the progression of a tumor.

Pancreatic cancer is a highly fatal disease with a high mortality rate and a 5-year survival rate of ~5% (16). Pancreatic cancer lacks noticeable symptoms, progresses rapidly, and is characterized by early dissemination and poor prognosis (17).
The present study revealed that D6R is able to suppress the proliferation and epithelial-mesenchymal transition (EMT) of pancreatic cancer cells. The results of the present study indicated that D6R may function as an ideal compound for anti-pancreatic cancer treatment.

Materials and methods

**Cell culture.** Pancreatic cancer SW1990 and PaTu8988 cell lines were obtained from the Second Military Medical University (Shanghai, China). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) with 10% fetal bovine serum (FBS; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37°C in a humidified incubator with a 5% CO₂ supply. Cells were treated with or without D6R (Fumeisi Biotechnology Co., Ltd., Nanjing, China) (1 μg/ml) for 48-72 h.

**Cell proliferation assay.** A Cell Counting Kit-8 (CCK-8, Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) was used to analyze cell viability. Briefly, cells were seeded onto a 96-well plate at 2,000 cells/well. A CCK-8 assay was used to assess the cell viability at the first, second, third, fourth and fifth day. Briefly, 10 μl CCK-8 was added to each well respectively and cells were incubated in the dark at 37°C for 2 h, and absorbance was measured at 490 nm with a iMark™ microplate absorbance reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

**Colony formation assay.** A colony formation assay was then used to detect the anchorage-independent growth of SW1990 and PaTu8988 cells. Cells were incubated in 6-well culture plates at 1,000 cells/well. The cell colonies were formed following incubation for 1-2 weeks, and then they were fixed with 4% paraformaldehyde (http://www.aladdin-e.com, Aladdin Shanghai Biochemical Technology Co., Ltd., Shanghai, China) for 20 min and stained with crystal violet (Aladdin Shanghai Biochemical Technology Co., Ltd.) for 30 min at room temperature. The numbers of colonies were counted and a graph was constructed.

**Scratch wound healing assay.** Scratch wound healing assay was used to detect the migration ability of SW1990 and PaTu8988 cells. Cells were seeded in a 24-well plate at 2x10⁴ cells/well and incubated for 6 h, then a 10-μl pipette tip was used to disrupt the confluent monolayer and the cell layer was washed with PBS three times. The width of scratch was visualized using a light microscope (magnification, x4; Olympus Corporation, Tokyo, Japan). Cells were then cultured in DMEM with or without 1 μg/ml D6R for 24 h. The wounded monolayer was visualized using a light microscope (magnification, x4; Olympus Corporation, Tokyo, Japan).

**Cell invasion assay.** Cell invasion assays were performed using Transwell chambers (Corning, NY, USA) according to the manufacturer's protocol. A total of 4 μl BD Matrigel Basement Membrane matrix (BD Biosciences, Franklin Lakes, NJ, USA) was placed in each chamber. Cells were seeded at a density of 1x10⁴ cells/well in Matrigel chambers in DMEM, and 10% FBS was added to the lower chambers. Following incubation for 24 h, with or without 1 μg/ml D6R, cells that remained on top of the filter were wiped off, and cells that had invaded to the lower chamber were stained and counted. Cells were fixed with 4% paraformaldehyde for 20 min and stained with 1% crystal violet for 30 min at room temperature. The numbers of invaded cells were counted and a graph was constructed.

**Western blotting.** Cells were rinsed with PBS 3 times on ice prior to treatment with radioimmunoprecipitation assay lysis buffer (Shanghai BioSun Sci&Tech Co., Ltd., Shanghai, China) at 100°C for 10 min. The mixture was then centrifuged at 4°C at 9,000 x g/min (Heal Force Development Ltd, Hong Kong, SAR, China) for 10 min. The supernatant was removed and the total cellular protein concentration was measured using the BCA method. Approximately 30 μg of protein was loaded in each lane and separated using SDS-PAGE (10% gel) and transferred onto polyvinylidene fluoride membranes. Membranes were blocked with 5% non-fat milk at room temperature for 1 h, then incubated with the primary antibodies at 4°C for 8 h and then secondary horseradish peroxidase (HRP)-conjugated antibodies at room temperature for 1 h. Bands were detected using an enhanced chemiluminescence system (Minichemill, SageCreation, Beijing, China). Primary antibodies included: rabbit anti-Furin (1:500; cat no. 18413-1-AP; Proteintech Group, Inc., Chicago, IL, USA) and mouse anti-β-Tubulin (1:10,000, cat no. 6181), rabbit anti-N-Cadherin (1:1,000; cat no. 13116), rabbit anti-E-Cadherin (1:1,000; cat no. 3195), rabbit anti-Vimentin (1:1,000; cat no. 5741), rabbit anti-DBF2 kinase activator protein MOBI (Mobi; 1:1,000, cat no. 313730), rabbit anti-p-Mobi (1:1,000, cat no. 8699), rabbit anti-yes-associated protein (YAP; 1:1,000; cat no. 8418), rabbit anti-p-YAP (1:1,000, cat no. 13619) (all purchased from Cell Signaling Technology, Inc., Danvers, MA, USA). The secondary HRP-conjugated antibodies were goat anti-rabbit IgG (H+L) secondary antibodies (1:10,000; cat no. 31460; Invitrogen; Thermo Fisher Scientific) and goat anti-mouse IgG (H+L) (1:5,000; cat no. 31430; Invitrogen; Thermo Fisher Scientific).

**Statistical analysis.** All data were presented as the mean ± the standard deviation. All statistical analyses were carried out using SPSS Statistical software (version 19; IBM Corp., Armonk, NY, USA). An unpaired Student's t-test was used to compare the significance between the experimental group and the control. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**D6R inhibits the proliferation of SW1990 and PaTu8988 cells.** CCK-8 assays were used to examine the relative proliferation rates in SW1990 and PaTu8988 cells. As presented in Fig. 1, D6R treatment resulted in decreased relative rates of proliferation in SW1990 and PaTu8988 cells, indicating that D6R inhibited the proliferation of SW1990 and PaTu8988 cells. Furthermore, a colony-forming assay revealed that the number of colonies were 468±19 in D6R-free and D6R-treated groups of SW1990 cells, respectively, and 603±21 and 234±19 in D6R-free and D6R-treated groups of PaTu8988 cells, respectively (Fig. 2). D6R treated cells demonstrated a significantly decreased number of colonies (P<0.05) for SW1990 and PaTu8988 cell lines compared with the untreated groups.
suggesting that D6R suppresses anchorage-independent growth. This data suggests that D6R inhibited the proliferation ability of SW1990 and PaTu8988 cells.

**D6R reduces cell invasiveness in SW1990 and PaTu8988 cells.** A Transwell invasion assay was used to examine the effect of D6R on the invasive abilities of SW1990 and PaTu8988 cells. As presented in Fig. 3, the numbers of invaded cells were 610±27 and 306±15 in D6R-free and D6R treated groups of SW1990 cells, respectively, and 203±16 and 87±20 in D6R-free and D6R treated groups of PaTu8988 cells, respectively. The number of invaded cells was significantly lower in the D6R treated groups for SW1990 and PaTu8988 cell lines (P<0.05) compared with the untreated groups. This data suggests that D6R inhibited the invasion ability of SW1990 and PaTu8988 cells.

**D6R inhibits the migration ability of SW1990 and PaTu8988 cells.** To determine the function of D6R in cell migration, a wound-healing assay was used to detect the migration ability of SW1990 and PaTu8988 cells. The width of the scratch at the beginning was 0.890±0.106 and 1.043±0.210 in D6R-free and D6R treated groups of SW1990 cells, respectively, and 0.893±0.182 and 1.228±0.201 in D6R-free and D6R treated groups of PaTu8988 cells, respectively. The number of invaded cells was significantly lower in the D6R treated groups for SW1990 and PaTu8988 cell lines (P<0.05) compared with the untreated groups. This data suggests that D6R inhibited the invasion ability of SW1990 and PaTu8988 cells.

**D6R inhibits EMT in SW1990 and PaTu8988 cells.** To determine whether D6R affects EMT, the expression of EMT relative proteins were examined with or without D6R treatment. Fig. 5A demonstrates that D6R resulted in the downregulation of N-cadherin and vimentin, and the upregulation of E-cadherin in SW1990 and PaTu8988 cells. Mature furin expression was slightly increased in cells treated with D6R, thus suggesting that D6R suppressed the activity of furin, and may have caused to some extent an
accumulation of the enzyme. This data confirms that D6R suppressed EMT in SW1990 and PaTu8988 cells.

**Discussion**

In the present study, it was identified that D6R, functioning as a furin inhibitor, suppressed the proliferation, migration and invasion of SW1990 and PaTu8988 cells, and characterized furin as an oncogene. Notably, D6R inhibited EMT potentially via the Hippo-YAP signaling pathway.

Differing types of small molecule components, including α1-PDX, Furin propeptide and proteinase inhibitor-8, which function as competitive furin inhibitors, have been well characterized. A number of them demonstrated the potential to be used for the treatment of certain infections, including bacterial and viral infections, such as Pseudomonas aeruginosa exotoxin A, Bacillus anthraci and Hepatitis B (4,13,14). Additionally, a number of them have been reported to reduce the growth and invasiveness of numerous types of tumor cells (10,11,18,19). α1-PDX resulted in the reduction of the growth and invasive ability, and malignant phenotypes of HT-29 human colon carcinoma cells (18), glioma tumor cells (20) and head and neck squamous cell carcinoma cells (10). A small-molecule inhibitor of furin named CCG 8294 and decRVKR-CMK inhibited the maturation of MMPs and the invasiveness of human fibrosarcoma cells (11,21). However, collective studies have demonstrated the limitations of these inhibitors. It has been revealed that polyarginines were characterized by high potency, specificity and low toxicity (12,22), compared with other small molecules. Previous studies have demonstrated the potency of D6R treatment on viral and bacterium infections, such as Pseudomonas aeruginosa exotoxin A, Bacillus anthraci and Hepatitis B (4,13,14).

In the present study, it was confirmed that D6R treatment resulted in the downregulation of N-cadherin and vimentin, and the upregulation of E-cadherin, consistent with the reduction in the invasion and migration ability of SW1990 and PaTu8988 cells. Furthermore, it was conclusively demonstrated that D6R inhibited EMT in line with alterations in YAP phosphorylation levels and the total YAP protein level, suggesting that YAP was involved in the regulation of EMT suppressed by D6R in SW1990 and PaTu8988 cells. Despite these notable findings, further investigations are required to elucidate the mechanism of D6R in the regulation of EMT via the Hippo-YAP pathway.

In summary, the present study indicates that D6R reduced the proliferation, migration and invasive ability of SW1990 and PaTu8988 cells, and that D6R-suppressed EMT may be regulated via the Hippo-YAP signaling pathway. Altogether, D6R has the potential to be used as a drug candidate to ameliorate a malignant phenotype in SW1990 and PaTu8988 cells.

**Acknowledgements**

The present study was supported by the National Natural Science Foundation of China (grant nos. 81672402, 81472333 and 81372718) and the Natural Science Foundation of Jiangsu Province (grant no. BK20131247).

**References**


